Analysis of Expression of Programmed Cell Death Ligand 1 (PD-L1) and BRAF(V600E) Mutation in Thyroid Cancer

SIMPLE SUMMARY: Immune checkpoint inhibitors are expected to be used in clinical practice to treat thyroid cancer. Programmed cell death ligand 1 (PD-L1) is the ligand expressed on the surface of tumor cells. Recent studies have reported that PD-L1 overexpression can impede T cell activation and res...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekino, Mizuki, Iwadate, Manabu, Yamaya, Yukie, Matsumoto, Yoshiko, Suzuki, Satoshi, Mizunuma, Hiroshi, Nakano, Keiichi, Nakamura, Izumi, Suzuki, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341229/
https://www.ncbi.nlm.nih.gov/pubmed/37444559
http://dx.doi.org/10.3390/cancers15133449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341229/
https://www.ncbi.nlm.nih.gov/pubmed/37444559
http://dx.doi.org/10.3390/cancers15133449

Ejemplares similares